相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
IQGAP2 Inhibits Migration and Invasion of Gastric Cancer Cells via Elevating SHIP2 Phosphatase Activity
Liang Xu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Multi-Institutional Randomized Double-Blind Phase II Trial of Everolimus vs. Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
C.A.O. Nathan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations
Hye Won Lee et al.
CLINICAL CANCER RESEARCH (2020)
Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas
Mara Gilardi et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
Irem Ozkan-Dagliyan et al.
CELL REPORTS (2020)
Biological role of epithelial-mesenchymal-transition-inducing transcription factors in head and neck squamous cell carcinoma: A systematic review
Everton Freitas de Morais et al.
ARCHIVES OF ORAL BIOLOGY (2020)
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Kirsten L. Bryant et al.
NATURE MEDICINE (2019)
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
Conan G. Kinsey et al.
NATURE MEDICINE (2019)
Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions
Hsiang-Fong Kao et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations
Alan Ho et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers
Brian R. Untch et al.
CANCER RESEARCH (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
1046OPreliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations
A L Ho et al.
ANNALS OF ONCOLOGY (2018)
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Tsukasa Shibue et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
Tikvah K. Hayes et al.
CANCER CELL (2016)
Protein Kinase CK2 Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2 Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma
Bingying Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma
Friederike Braig et al.
ONCOTARGET (2016)
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Adrienne D. Cox et al.
CLINICAL CANCER RESEARCH (2015)
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence et al.
NATURE (2015)
HiTSelect: a comprehensive tool for high-complexity-pooled screen analysis
Aaron A. Diaz et al.
NUCLEIC ACIDS RESEARCH (2015)
Analysis of drug combinations: current methodological landscape
Julie Foucquier et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
T. Rampias et al.
CLINICAL CANCER RESEARCH (2014)
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells
J. Hun Hah et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem et al.
SCIENCE (2014)
Consistent and Differential Genetic Aberrations between Esophageal Dysplasia and Squamous Cell Carcinoma Detected By Array Comparative Genomic Hybridization
Zhi-Zhou Shi et al.
CLINICAL CANCER RESEARCH (2013)
Recent advances in protein prenyltransferases: substrate identification, regulation, and disease interventions
Elaina A. Zverina et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2012)
Regulating the regulator: post-translational modification of RAS
Ian M. Ahearn et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Targeting protein prenylation for cancer therapy
Norbert Berndt et al.
NATURE REVIEWS CANCER (2011)
Restoration of E-cadherin Cell-Cell Junctions Requires Both Expression of E-cadherin and Suppression of ERK MAP Kinase Activation in Ras-Transformed Breast Epithelial Cells
Quanwen Li et al.
NEOPLASIA (2008)
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling - Role in FTI enhancement of taxane and tamoxifen anti-tumor activity
AD Basso et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity
TS Reid et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner
AF Castro et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
分享论文
